An Open-Label, First-in-Human Study Evaluating the Safety, Tolerability, and Efficacy of VCTX211 Combination Product in Subjects With Type 1 Diabetes Mellitus (T1D)
CRISPR Therapeutics AG is advancing VCTX211, a combination product aimed at treating Type 1 Diabetes Mellitus (T1D) through innovative gene editing technology. The asset is positioned in a competitive landscape with a growing focus on cell therapies and gene editing for autoimmune diseases. The termination of the trial indicates a strategic pivot to follow-up studies (VCTX-201), which may enhance patient outcomes and data robustness. The T1D market is substantial, with increasing demand for novel therapies that offer improved glycemic control and reduced reliance on exogenous insulin. The collaboration with ViaCyte adds credibility and expertise in cell therapy, potentially strengthening market positioning.
Indication: Diabetes Mellitus
Modality: gene therapy
Target: Allogeneic pancreatic endoderm cells (PEC211) genetically modified using CRISPR/Cas9 to promote immune evasiveness and survival.
Sponsor: CRISPR Therapeutics AG
Source URL: ClinicalTrials.gov
Source updated: May 07, 2026
Ingested: Jun 12, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: Allogeneic pancreatic endoderm cells (PEC211) genetically modified using CRISPR/Cas9 to promote immune evasiveness and survival.
View original source fields
Condition raw: Diabetes Mellitus, Diabetes Mellitus, Type 1, Glucose Metabolism Disorders, Metabolic Disease, Endocrine System Diseases, Autoimmune Diseases, Immune System Diseases
Condition normalized: Diabetes Mellitus, Diabetes Mellitus, Type 1, Glucose Metabolism Disorders, Metabolic Disease, Endocrine System Diseases, Autoimmune Diseases, Immune System Diseases
Modality raw: gene therapy
Modality normalized: gene therapy
Target raw: Allogeneic pancreatic endoderm cells (PEC211) genetically modified using CRISPR/Cas9 to promote immune evasiveness and survival.
Target normalized: Allogeneic pancreatic endoderm cells (PEC211) genetically modified using CRISPR/Cas9 to promote immune evasiveness and survival.